# BMJ Open: first published as 10.1136/bmjopen-2021-052629 on 26 August 2021. Downloaded from http://bmjopen.bmj.com/ on September 15, 2021 at University of Worcester. Protected by

# BMJ Open Using patient-reported outcome measures during the management of patients with end-stage kidney disease requiring treatment with haemodialysis (PROM-HD): a qualitative study

Nicola Elzabeth Anderson (b), 1,2,3 Christel McMullan (b), 3,4 Melanie Calvert (b), 3,4,5,6,7 Mary Dutton, 1,2,3 Paul Cockwell, 2,3 Olalekan L Aiyegbusi, 3,5,6,7 Derek Kyte 6 3,8

To cite: Anderson NE. McMullan C, Calvert M, et al. Using patient-reported outcome measures during the management of patients with end-stage kidney disease requiring treatment with haemodialysis (PROM-HD): a qualitative study. BMJ Open 2021;11:e052629. doi:10.1136/ bmjopen-2021-052629

Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (http://dx.doi.org/10.1136/ bmjopen-2021-052629).

Received 27 April 2021 Accepted 06 July 2021



@ Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.

For numbered affiliations see end of article.

### **Correspondence to**

Mrs Nicola Elzabeth Anderson; NEA451@bham.ac.uk

### **ABSTRACT**

**Objectives** Patients undergoing haemodialysis report elevated symptoms and reduced health-related quality of life, and often prioritise improvements in psychosocial well-being over long-term survival. Systematic collection and use of patient-reported outcomes (PROs) may help support tailored healthcare and improve outcomes. This study investigates the methodological basis for routine PRO assessment, particularly using electronic formats (ePROs), to maximise the potential of PRO use, through exploration of the experiences, views and perceptions of patients and healthcare professionals (HCPs) on implementation and use of PROs in haemodialysis settings. Study design Qualitative study.

Setting and participants Semistructured interviews with 22 patients undergoing haemodialysis, and 17 HCPs in the

Analytical approach Transcripts were analysed deductively using the Consolidated Framework for Implementation Research (CFIR) and inductively using thematic analysis.

Results For effective implementation, the potential value of PROs needs to be demonstrated empirically to stakeholders. Any intervention must remain flexible enough for individual and aggregate use, measuring outcomes that matter to patients and clinicians, while maintaining operational simplicity. Any implementation must sit within a wider framework of education and support for both patients and clinicians who demonstrate varying previous experience of using PROs and often confuse related concepts. Implementation plans must recognise the multidimensionality of end-stage kidney disease and treatment by haemodialysis, while acknowledging the associated challenges of delivering care in a highly specialised environment. To support implementation, careful consideration needs to be given to barriers and facilitators including effective leadership, the role of champions, effective launch and ongoing evaluation. Conclusions Using the CFIR to explore the experiences, views and perceptions of key stakeholders, this study identified key factors at organisational and individual levels which could assist effective implementation of ePROs in

### Strengths and limitations of this study

- Qualitative methods yield rich data with face-to-face semistructured interviews allowing the interviewer to monitor non-verbal communications and clarify ambiguous responses.
- This study involved explorations of a prospective intervention, meaning some participants were unfamiliar with key concepts. Preinterview materials were shared to support and inform discussion and participation.
- The role of the researchers was carefully considered to acknowledge and minimise bias associated with beliefs and values. Steps were taken to mitigate risks, including use of reflective diaries, participant checking and multiple researchers involved in the coding process.
- While purposive sampling methods led to a diverse sample of participants, it is acknowledged that the sample did not include non-English speakers or carers. Further research is required.
- Data were collected before the coronavirus pandemic. The healthcare delivery landscape in the UK has changed, and it is possible that some attitudes and beliefs particularly around digital data capture may have evolved.

haemodialysis settings. Further research will be required to evaluate subsequent ePRO interventions to demonstrate the impact and benefit to the dialysis community.

### INTRODUCTION

The prevalence of end-stage kidney disease (ESKD) requiring treatment with renal replacement therapies such as haemodialysis (HD) continues to rise worldwide. Both underlying disease and treatment are associated with a high symptom burden and reduced health-related quality of life (HRQoL).2 3 Historically, outcomes such as mortality and



dialysis adequacy based on biomedical parameters have been used to inform the management of dialysis services and individual care. However, there is now a body of established research<sup>5–10</sup> demonstrating the importance of also capturing patient-reported outcomes (PROs). PRO measures capture data directly from patients on how they feel or function, without requiring interpretation from others, using standardised symptom and/or QoL questionnaires, <sup>11</sup> and are often in electronic format (ePROs).

However, while patient-reported experience measures (PREMs), which allow patients to self-report their experience of receiving healthcare, have been collected since 2017,<sup>12</sup> PROs are still not routinely and systematically collected to manage individual patient care in the UK: meaning that many patients and some members of the multidisciplinary team caring for them are inexperienced in PROs and related concepts.

Yet the international body of evidence exploring the use of PROs in nephrology settings is growing, <sup>13–22</sup> demonstrating acceptability and feasibility of ePRO capture<sup>23–25</sup> and how ePROs can support the delivery of patient-centred care. 26 27 However, the overall impact and benefit of PRO use in dialysis care is yet to be established.<sup>28</sup> In comparison, PRO research in oncology has shown defined benefits ranging from improved QoL and reduction in hospitalisations to overall survival<sup>29</sup> and even cost-effectiveness. 30

In November 2020, an online UK Summit led by the UK Renal Association, entitled 'ePROs for the Kidney Patient Community', was held to create a comprehensive, UK-wide roadmap to facilitate and optimise the collection and use of ePROs for the benefit of people with chronic kidney disease (CKD). This summit highlighted the importance of key stakeholder engagement, including patients and front-line clinicians, early and at all stages of design and implementation.<sup>31</sup>

To inform and direct future research plans, this study aimed to investigate the methodological basis for routine PRO assessment through exploration of the experiences, views and perceptions of patients and healthcare professionals (HCPs) on implementation and use of PROs, particularly ePROs, in HD settings.

### **METHODS** Design

The qualitative research question: 'What are the experiences, views and perceptions of patients undergoing HD on the implementation and use of ePROs in routine care and research settings?'

Epistemologically, pragmatism, which is set within a paradigm of enquiry processes and research practicality,<sup>32</sup> provides the philosophical framework to answer this question. A core assumption of pragmatism is that research should proceed from a wish to produce actionable knowledge<sup>33</sup>; allowing the researcher to select the research design and the methodology deemed most appropriate.<sup>34</sup> These foundations led to the decision to use the

Consolidated Framework for Implementation Research  $^{35}$ to offer a theoretical perspective and a qualitative descriptive (QD) methodology. 36-38 This is particularly useful for healthcare studies focused on discovering the who, what and where of events or experiences and gaining understanding of inadequately understood phenomenon. Kim et al<sup>68</sup> describe QD as the 'label of choice' when an unambiguous description of a phenomenon is desired or information is sought to develop and refine questionnaires or interventions.<sup>39</sup> This choice of methodology led to the utilisation of the following methods.

### **Participant selection**

Participants included adults (≥18 years), receiving HD (in centre or at home), able to provide valid informed consent and converse in everyday English. Patients were excluded if they were not deemed established on HD or had been undergoing HD <3 months, or if they had an active intercurrent medical problem requiring enhanced routine clinical care. 40 Participants were identified and recruited between July 2018 and November 2019 by the lead author. Eligible patients were primarily approached face to face in the dialysis unit; patients dialysing in centre were approached before dialysis session and patients who dialysed at home (home haemodialysis (HHD)) were approached when they attended for clinic. Purposive sampling was undertaken to achieve maximum variation across age, gender, ethnicity, time on dialysis and comorbidities. 41 HCPs were recruited from the broader renal team, and initially contacted by email by the lead author; they included healthcare and administrative assistants.<sup>40</sup>

### Setting

Data were collected from 22 patients undergoing HD and 17 HCPs in the UK (see tables 1 and 2). All participants were being treated via, or working at, a large regional hospital. To accurately reflect the diversity within the dialysis population, patients being treated in centre (n=15) were recruited from two satellite units as well as seven patients choosing to dialyse at home. Non-medical members of the multidisciplinary team were targeted from these two units, one in a city and one serving mainly rural communities. All HCPs currently working in the home setting (n=5) had extensive previous experience of in-centre dialysis delivery.

### **Data collection**

All consenting participants took part in an audio-recorded semistructured interview with the lead author, either face to face or by telephone. Ethical approval was gained for follow-up interviews, but none were required. Patient interviews were conducted at the dialysis unit for those dialysing in centre (n=15) and at home for the HHD group (n=7). Since these interviews were conducted in patient homes, family members were sometimes present at the request of the patient, but did not take an active role in the interview. HCPs were interviewed in a private room at their workplace. Topic guides were used to steer



Variable         Count (%)           Age         <40         2/22 (9)           40-49         3/22 (13)         50-59         5/22 (23)           60-69         3/22 (14)         70-79         6/22 (27)           >80         3/22 (13)         Gender           Male         12/22 (55)         Female         10/22 (45)           Ethnicity         White         16/22 (73)         British           Black         4/22 (18)         British         Black         British           Black British         15/22 (68)         British	Table 1 Patient participant char	acteristics
<40       2/22 (9)         40-49       3/22 (13)         50-59       5/22 (23)         60-69       3/22 (14)         70-79       6/22 (27)         >80       3/22 (13)         Gender       Male       12/22 (55)         Female       10/22 (45)         Ethnicity       White       16/22 (73)         British       Black       4/22 (18)         British       British       British         In-centre       15/22 (68)         dialysis       12/15 (80)         Morning sessions       12/15 (80)         Home HD       7/22 (32)         Current vascular access         Arteriovenous fistula       19/22 (86)         Arteriovenous graft       0/22 (0)         Central venous catheter       3/22 (14)         Charlson Comorbidity Score         <2       1 (4)         3-4       5 (23)         5-6       4 (18)         7-8       6 (27)         9-10       5 (23)         11-12       1 (4)         13+       0 (0)         Time since dialysis commencement (years)         ≤5       11/22 (50)         6-10 </th <th>Variable</th> <th>Count (%)</th>	Variable	Count (%)
<40	Age	
50-59 5/22 (23) 60-69 3/22 (14) 70-79 6/22 (27) >80 3/22 (13) Gender  Male 12/22 (55) Female 10/22 (45)  Ethnicity  White 16/22 (73) British  Black 4/22 (18) British  Asian/Asian 2/22 (9) British  In-centre dialysis  Morning sessions 12/15 (80) Home HD 7/22 (32)  Current vascular access  Arteriovenous fistula 19/22 (86) Arteriovenous graft 0/22 (0) Central venous catheter 3/22 (14)  Charlson Comorbidity Score  <2 1 (4) 3-4 5 (23) 5-6 4 (18) 7-8 6 (27) 9-10 5 (23) 11-12 1 (4) 13+ 0 (0)  Time since dialysis commencement (years) ≤5 11/22 (50) 6-10 5/22 (23) 11-15 3/22 (14) 16-20 1/22 (4.5)		2/22 (9)
60-69 3/22 (14) 70-79 6/22 (27) >80 3/22 (13) Gender  Male 12/22 (55) Female 10/22 (45)  Ethnicity  White 16/22 (73) British  Black 4/22 (18) British  Asian/Asian 2/22 (9) British  In-centre dialysis  Morning sessions 12/15 (80) Home HD 7/22 (32)  Current vascular access  Arteriovenous fistula 19/22 (86) Arteriovenous graft 0/22 (0) Central venous catheter 3/22 (14)  Charlson Comorbidity Score  <2 1 (4) 3-4 5 (23) 5-6 4 (18) 7-8 6 (27) 9-10 5 (23) 11-12 1 (4) 13+ 0 (0)  Time since dialysis commencement (years) ≤5 11/22 (50) 6-10 5/22 (23) 11-15 3/22 (14) 16-20 1/22 (4.5)	40–49	3/22 (13)
70–79 6/22 (27)  >80 3/22 (13)  Gender  Male 12/22 (55)  Female 10/22 (45)  Ethnicity  White 16/22 (73)  British  Black 4/22 (18)  British  Asian/Asian 2/22 (9)  British  In-centre 15/22 (68)  dialysis  Morning sessions 12/15 (80)  Home HD 7/22 (32)  Current vascular access  Arteriovenous fistula 19/22 (86)  Arteriovenous graft 0/22 (0)  Central venous catheter 3/22 (14)  Charlson Comorbidity Score  <2 1 (4)  3-4 5 (23)  5-6 4 (18)  7-8 6 (27)  9-10 5 (23)  11-12 1 (4)  13+ 0 (0)  Time since dialysis commencement (years)  ≤5 11/22 (50)  6-10 5/22 (23)  11-15 3/22 (14)  16-20 1/22 (4.5)	50–59	5/22 (23)
Sender  Male  Male  12/22 (55)  Female  10/22 (45)  Ethnicity  White  Black  British  Asian/Asian  British  In-centre  dialysis  Morning sessions  12/15 (80)  Home HD  7/22 (32)  Current vascular access  Arteriovenous fistula  Arteriovenous graft  Central venous catheter  3/22 (14)  Charlson Comorbidity Score  <2  1 (4)  3-4  5 (23)  5-6  4 (18)  7-8  6 (27)  9-10  5 (23)  11-12  1 (4)  13+  0 (0)  Time since dialysis commencement (years)  ≤5  11/22 (50)  6-10  5/22 (23)  11-15  3/22 (14)  16-20  1/22 (4.5)	60–69	3/22 (14)
Gender         Male       12/22 (55)         Female       10/22 (45)         Ethnicity       Incepted (18)         White       16/22 (73)         British       Incepted (18)         Asian/Asian       2/22 (9)         British       Incentre         dialysis       15/22 (68)         Morning sessions       12/15 (80)         Home HD       7/22 (32)         Current vascular access       Arteriovenous fistula       19/22 (86)         Arteriovenous graft       0/22 (0)         Central venous catheter       3/22 (14)         Charlson Comorbidity Score       <2	70–79	6/22 (27)
Male       12/22 (55)         Female       10/22 (45)         Ethnicity       White         White       16/22 (73)         British       4/22 (18)         British       2/22 (9)         British       15/22 (68)         In-centre       15/22 (68)         dialysis       Morning sessions         Morning sessions       12/15 (80)         Home HD       7/22 (32)         Current vascular access         Arteriovenous fistula       19/22 (86)         Arteriovenous graft       0/22 (0)         Central venous catheter       3/22 (14)         Charlson Comorbidity Score         <2	>80	3/22 (13)
Ethnicity  White	Gender	
Ethnicity  White British  Black 4/22 (18)  British  Asian/Asian 2/22 (9)  British  In-centre 15/22 (68)  dialysis  Morning sessions 12/15 (80)  Home HD 7/22 (32)  Current vascular access  Arteriovenous fistula 19/22 (86)  Arteriovenous graft 0/22 (0)  Central venous catheter 3/22 (14)  Charlson Comorbidity Score  <2 1 (4)  3-4 5 (23)  5-6 4 (18)  7-8 6 (27)  9-10 5 (23)  11-12 1 (4)  13+ 0 (0)  Time since dialysis commencement (years)  ≤5 11/22 (50)  6-10 5/22 (23)  11-15 3/22 (14)	Male	12/22 (55)
White British       16/22 (73)         Black British       4/22 (18)         Asian/Asian British       2/22 (9)         In-centre dialysis       15/22 (68)         Morning sessions       12/15 (80)         Home HD       7/22 (32)         Current vascular access       Arteriovenous fistula       19/22 (86)         Arteriovenous graft       0/22 (0)         Central venous catheter       3/22 (14)         Charlson Comorbidity Score       <2	Female	10/22 (45)
British  Black British  Asian/Asian British  In-centre dialysis  Morning sessions  Inourier	Ethnicity	
British         Asian/Asian British       2/22 (9)         In-centre dialysis       15/22 (68)         Morning sessions       12/15 (80)         Home HD       7/22 (32)         Current vascular access       Arteriovenous fistula       19/22 (86)         Arteriovenous graft       0/22 (0)         Central venous catheter       3/22 (14)         Charlson Comorbidity Score       <2		16/22 (73)
British   In-centre   15/22 (68)   dialysis     Morning sessions   12/15 (80)     Home HD   7/22 (32)     Current vascular access     Arteriovenous fistula   19/22 (86)     Arteriovenous graft   0/22 (0)     Central venous catheter   3/22 (14)     Charlson Comorbidity Score     <2		4/22 (18)
dialysis         Morning sessions       12/15 (80)         Home HD       7/22 (32)         Current vascular access         Arteriovenous fistula       19/22 (86)         Arteriovenous graft       0/22 (0)         Central venous catheter       3/22 (14)         Charlson Comorbidity Score       <2		2/22 (9)
Home HD       7/22 (32)         Current vascular access       19/22 (86)         Arteriovenous graft       0/22 (0)         Central venous catheter       3/22 (14)         Charlson Comorbidity Score       2         <2		15/22 (68)
Current vascular access         Arteriovenous fistula       19/22 (86)         Arteriovenous graft       0/22 (0)         Central venous catheter       3/22 (14)         Charlson Comorbidity Score       -2         <2	Morning sessions	12/15 (80)
Arteriovenous fistula       19/22 (86)         Arteriovenous graft       0/22 (0)         Central venous catheter       3/22 (14)         Charlson Comorbidity Score       2         <2	Home HD	7/22 (32)
Arteriovenous graft 0/22 (0)  Central venous catheter 3/22 (14)  Charlson Comorbidity Score  <2 1 (4)  3-4 5 (23)  5-6 4 (18)  7-8 6 (27)  9-10 5 (23)  11-12 1 (4)  13+ 0 (0)  Time since dialysis commencement (years)  ≤5 11/22 (50)  6-10 5/22 (23)  11-15 3/22 (14)  16-20 1/22 (4.5)	Current vascular access	
Central venous catheter       3/22 (14)         Charlson Comorbidity Score         <2	Arteriovenous fistula	19/22 (86)
Charlson Comorbidity Score         <2	Arteriovenous graft	0/22 (0)
<2 3-4 5 (23)  5-6 4 (18)  7-8 6 (27)  9-10 5 (23)  11-12 1 (4)  13+ 0 (0)  Time since dialysis commencement (years)  ≤5 11/22 (50)  6-10 5/22 (23)  11-15 3/22 (14)  16-20 1/22 (4.5)	Central venous catheter	3/22 (14)
3-4 5 (23) 5-6 4 (18) 7-8 6 (27) 9-10 5 (23) 11-12 1 (4) 13+ 0 (0) Time since dialysis commencement (years) ≤5 11/22 (50) 6-10 5/22 (23) 11-15 3/22 (14) 16-20 1/22 (4.5)	Charlson Comorbidity Score	
5-6 4 (18)  7-8 6 (27)  9-10 5 (23)  11-12 1 (4)  13+ 0 (0)  Time since dialysis commencement (years)  ≤5 11/22 (50)  6-10 5/22 (23)  11-15 3/22 (14)  16-20 1/22 (4.5)	<2	1 (4)
7-8 6 (27)  9-10 5 (23)  11-12 1 (4)  13+ 0 (0)  Time since dialysis commencement (years)  ≤5 11/22 (50)  6-10 5/22 (23)  11-15 3/22 (14)  16-20 1/22 (4.5)	3–4	5 (23)
9-10 5 (23)  11-12 1 (4)  13+ 0 (0)  Time since dialysis commencement (years)  ≤5 11/22 (50)  6-10 5/22 (23)  11-15 3/22 (14)  16-20 1/22 (4.5)	5–6	4 (18)
11–12 1 (4)  13+ 0 (0)  Time since dialysis commencement (years)  ≤5 11/22 (50)  6–10 5/22 (23)  11–15 3/22 (14)  16–20 1/22 (4.5)	7–8	6 (27)
13+     0 (0)       Time since dialysis commencement (years)       ≤5     11/22 (50)       6-10     5/22 (23)       11-15     3/22 (14)       16-20     1/22 (4.5)	9–10	5 (23)
Time since dialysis commencement (years)  ≤5 11/22 (50)  6–10 5/22 (23)  11–15 3/22 (14)  16–20 1/22 (4.5)	11–12	1 (4)
≤5 11/22 (50) 6–10 5/22 (23) 11–15 3/22 (14) 16–20 1/22 (4.5)	13+	0 (0)
6–10 5/22 (23) 11–15 3/22 (14) 16–20 1/22 (4.5)	Time since dialysis commenceme	ent (years)
11–15 3/22 (14) 16–20 1/22 (4.5)	≤5	11/22 (50)
16–20 1/22 (4.5)	6–10	5/22 (23)
	11–15	3/22 (14)
>20 2/22 (9)	16–20	1/22 (4.5)
	>20	2/22 (9)

Charlson Comorbidity Index (CCI)<sup>65</sup> quantifies an individual's burden of disease and corresponding 1-year mortality risk. The index adjusts for 17 comorbidities, each one classified with a validated score of 1–6 points, based on the adjusted relative risk of 1-year mortality. The final total score is used to calculate the probability of survival. The index is being used in this context to demonstrate the overall disease burden of the population under study.

n=22.

HD, haemodialysis.

Table 2         Healthcare professional participar	nt characteristics
Variable	Count (%)
Gender	
Male	5/17 (29)
Female	12/17 (71)
Ethnicity (Office of National Statistics categories	ories)
White British	9/17 (53)
Other white background	2/17 (12)
Black British	1/17 (6)
Asian/Asian British	1/17 (6)
Any other Asian background	2/17 (12)
Black African	1/17 (6)
White and Black Caribbean	1/17 (6)
Role	
Consultant nephrologist	5/17 (29)
Consultant surgeon	1/17 (6)
Registered nurse	9/17 (53)
Non-registered healthcare assistant	1/17 (6)
Administrative assistant	1/17 (6)
Time working across HD setting (years)	
≤5	1/17 (6)
6–10	4/17 (24)
11–15	3/17 (18)
16–20	2/17 (12)
>20	7/17 (41)

n=17.

HD, haemodialysis.

and support the interview process (see online supplemental files 1 and 2). These guides were piloted with one participant from each group and then refined iteratively during the collection phase in response to initial findings. Field notes and in-depth memos were created after each interaction. Since PROs are not routinely collected in the UK, including the hospital trust where this research was undertaken, it was recognised preinterview information was required to aid the quality of discussion around PROs and future implementation. Therefore, participants were provided with a diagram of a core outcome set selected specifically for use in HD trials, to illustrate the position of PROs in outcome measurement<sup>42</sup> and example PROs from a recent systematic review and supported by our local renal public and patient involvement group: Kidney Disease Quality of Life Short Form, 43 Kidney Disease Quality of Life 3644 and Integrated Patient Outcome Scale-Renal. 45 Patients in all UK renal units are invited to complete the annual renal PREM to report their experience of kidney care. This report demonstrates variation in experience across centres and can be used to drive organisational change and improvement<sup>12</sup>; some patient

### The Consolidated Framework for Implementation Research (CFIR)

### IMPLEMENTATION OF PATIENT REPORTED OUTCOME MEASURES IN HAEMODIALYSIS SETTINGS Individual Intervention Outer Setting Inner Setting Process Characteristics Characteristics Source Structural Knowledge and Planning Patient Needs and Evidence Strength & Characteristics beliefs about the Engaging Resources Quality Networks and intervention Opinion Leaders Cosmopolitanism Relative Advantage Self-efficacy Communications Executing Peer Pressure Adaptability Culture Reflecting and Stage of change External Policy and Trialability Implementation Evaluating Identification with Incentives Complexity Climate organisation Design Readiness for Other personal Cost implementation attributes KEY FINDINGS Barriers: workload, time Importance of Important to Compatibility of PROs Previous experience of using factors, infrastructure. identify and demonstrating PROs use and delivery of care PROS Facilitators: Leadership, efficacy measure 'outcomes in HD settings PROs v PREMs Champions, effective that matter' to Any intervention must be A wider educational Multidimensional aspects of launch, intervention flexible/offer choices for patients framework - 'the End Stage Kidney Disease The 'Bigger picture' evaluation, delivery of key practical considerations information loop relative advantage and how PROs fit

Adapted from Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implement Sci. 2009;4:50.

Figure 1 Conceptual framework and key findings (adapted from Damschroder et  $al^{35}$ ). HD, haemodialysis; PREM, patientreported experience measure; PRO, patient-reported outcome.

participants indicated they had completed the annual PREM.

### **Analysis**

Using codebook thematic analysis, <sup>46</sup> a coding framework, drawing on the Consolidated Framework for Implementation Research (CFIR), 35 was used to deductively analyse transcripts, with further new subthemes developed inductively through data engagement and the analytical

The CFIR is a widely used conceptual framework developed to guide systematic assessment of factors that might influence implementation and effectiveness, including assessing potential barriers and facilitators in preparation for implementing an innovation (see figure 1). 35 47 Primary data analysis was conducted by the lead author, with two investigators (CMcM, DK) reviewing coding for consistency and appropriateness. As the lead author was a renal research nurse conducting this research as part of a Clinical Doctoral Research Fellowship, she was known to some HCP participants. This information was declared and discussed during the valid informed consent process. Additionally, a reflective research diary, memo writing and discussion with the study management team were used to try to minimise the influence of prior relationships on analysis. Data analysis was supported by qualitative data analysis software—QSR NVivo V.12. Participant verification, 48 to check that the transcript correctly documented

the discussion, was undertaken on one transcript from each group—no discrepant comments were reported. Data collection and analysis continued until saturation was achieved, that is, no new information pertinent to the research question was being generated by further interviews (see online supplemental tables 1 and 2).49

### **Patient and public involvement**

Research on the use and implementation of PROs in nephrology settings was prioritised by the local kidney patients charity. An existing patient and public involvement (PPI) group was used and a study-specific PPI group was convened to help develop the research question, design this study and the associated fellowship application. Patients were consulted on the study documentation, including topic guides and example materials (see online supplemental files 1 and 2). A summary of study findings will be made available for study participants.

### **RESULTS**

### **Participant characteristics**

Participant characteristics are summarised in tables 1 and

The patient sample was broadly representative of prevalent HD population in the UK.<sup>50</sup>

Data saturation was deemed achieved after interviewing 16 HCPs and 15 patients (see online supplemental tables 1 and 2 for further detail).



### **Key findings**

Analysis identified the following themes, which are presented in line with the CFIR key domains. Although presented in a linear fashion, the five domains and their respective constructs cannot be considered in isolation, all interact to effect implementation.

Figure 1 shows the conceptual framework and associated findings. Illustrative quotations are provided in table 3.

Intervention characteristics: factors associated with design and quality of the intervention, including how intervention is perceived *The importance of demonstrating PRO efficacy and impact* 

Both patients and HCP participants felt that PROs could support the delivery of person-centred care through shared decision-making and management in dialysis settings. However, HCP interviewees highlighted the key challenge was not the physical collection of PROs, but how the data were then used to improve outcomes. For patients, it was key that any time spent completing questionnaires should be rewarded with review and appropriate action, that is, not a 'tick-box' exercise.

HCPs, particularly nephrologists, extolled the importance of PROs in research settings.

### Intervention flexibility

The topic guide initiated discussions with participants on key practical considerations, including frequency (of PRO completion), optimal timing (around dialysis), preferred setting (home or in centre), favoured mode of administration (electronic or paper versions) and interpretation and feedback of the responses.

It was clear from the patients that a fixed means of implementing PROs would not meet the requirements of this heterogeneous group. Any system would need to be flexible while maintaining maximum simplicity. Most patients felt they could complete electronic measures if required, but some strongly favoured paper options. Most interviewees stated that self-completion was possible but felt some would need physical or emotional support from carers. A few patients indicated a desire for assistance with information technology (IT) aspects until they became familiar. Several patients alluded to the need to 'compartmentalise' their dialysis by conducting all dialysis-related activity in centre or by having discrete facilities and times for dialysis if being treated at home; suggesting that PRO completion would need to be undertaken at defined times/settings within their schedule. Others were less concerned about daily reminders of their disease and management, so were open to completion timings/ settings that were more variable.

HCPs discussed the promise of electronic capture to support enhanced management of chronic symptoms, but some expressed concerns about potentially missing acute signs and effectiveness of associated safety reporting and actions. Two HHD patients foresaw the potential benefits of automated safety alerts associated with electronic capture. However, one patient noted that it was

important that any automated information or self-help advice should not conflict with information given face to face by the doctor.

Participants were asked for their perspectives on computer adaptive technology, a type of assessment in which questions are generated specifically for each individual, using item response theory. This was a new concept to nearly all participants, but most quickly grasped the underlying theory after a short explanation and were supportive of the idea, recognising the potential to stop redundant questions and save time. (See table 4 for overview of practical considerations.)

Outer setting: the wider societal, economic and organisational contexts in which the stakeholders and organisation implementing the intervention reside

### Identifying outcomes that matter

There was a general agreement among all participants that it was important to ensure measurement of 'what outcomes matter most' to patients.<sup>51</sup> There was a broad agreement from patients that the example PROs they had been provided with were comprehensive in covering the key symptoms facing patients undertaking HD. Furthermore, they agreed with findings from the Standardised Outcomes in Nephrology (Haemodialysis) initiative (SONG-HD) <sup>42</sup> that fluctuations in HRQoL mattered more, to them, than biomedical outcomes. The importance of these outcomes was acknowledged by the HCPs, but it was felt that deep exploration of some PRO data fell outside the remit of the nephrologist or dialysis nurse and there was anxiety about acting outside their competency and the associated risks of litigation.

### The 'Bigger Picture'

Several patients highlighted problems with continuity of care and lack of cohesion between primary care and their dialysis provision. One HHD patient felt the use of PROs could assist uptake of home therapies by demonstrating better overall outcomes/HRQoL for patients managing their own dialysis. Participants in both groups reflected that PROs could help support shared decision-making by targeting and prioritising discussions according to the patient's agenda.

Inner setting: the structural and cultural contexts around where the implementation will take place

Compatibility of PRO use and approaches to care in HD settings

Discussing potential implementation and how participants perceive the current situation as needing change, patients and staff alike discussed the approaches to care within dialysis settings. Patients clearly described a 'task orientated' style of care in centre, with a focus on practically administering HD, versus a more patient-centred model discussed by those dialysing at home. HHD patients dialysing themselves felt they had developed a level of expertise and the increased 'control' had improved their HRQoL. They indicated current communication pathways were effective and that the HHD team was responsive

Table 3 Key findings—sum	Key findings—summary of direct quotes	
Key finding	Illustrative quotation	
1. Intervention characteristics	Patient participants	HCP participants
The importance of demonstrating efficacy/benefit	'If they haven't got a point for collecting them that isn't going to be actioned or put into a specific piece of research, then they shouldn't be there 'Yes, it makes you unwilling to invest your own time in something that you hadn't seen any benefit from	one is convincing those patients and doctors and nurses that it's [PROs] actually of use to man or beast. I think that is going to be the main barrier.' HCP11
The intervention must be flexible/ offer choices	in the past If it's just a box ticking exercise for your unit or whatever, to say that I've compiled with some directive and nothing is going to change, then why would you'.' Patient JI18	I think if you could then see that it changed a consultation that meant that you went, 'Oh, I didn't know you were having that issue; I can do something about that. The difficulty is if they then, it drives a lot of conversations that, you know, saying, 'Yeah, can't really do anything about then', and then everybody may well
Practical considerations	'Yeah, but certainly filling it in is not an issue, I think discussing it and whether somebody has their partner with them or carer or whatever, I think it's something you should offer them and it's for them to make up their mind.' Patient MNO7	think well this hasn't changed anything so, you know, is it making you teel better writing it down? Don't know really. So if there's not an outcome difference to it then it just becomes a kind of form-filling exercise but there's not obviously a benefit.' HCP16
	See table 4 for key findings and illustrative direct quotes.	I guess we have to give the option to the patient whether and how they want to fill this in or not because some patients may not want to fill it in. And I can think of a few patients on my dialysis unit that probably would not want to fill this in.' HCP14
2. Outer setting		
Identifying and measuring outcomes that matter	'I need to go out. I need to keep this going. I need to keep feeling that I'm worth something by bringing home a wage and working.' Patient YZ13	'Yes, definitely. We see that all the time don't we? I mean you know, we see that all the time. I mean that's the battle, to get people to dialyse three times a week rather than twice a week [yeah, yeah]. So you know, I'm having this battle with a man in XI hit at the moment who's decided to go and dialyse twice a week
How PROs fit into the 'Bigger Picture'	'It does really knock the quality of life, some people tend to be more worried about the quantity of life but I'm interested in the quality of life because not having quality of life, I can understand why some people do commit suicide, there's no quality.' Patient ST10	and he track if you are some the said, 'Oh, I feel perfectly well. So I'm just and he carry on dialysing twice a week' and I said, 'Well, that's not the point' [laughs] [absolutely]. And he said, 'Yeah, but I feel fine. I get more time, I get more spare time.' HCP13
	Continuity of care and communication with primary care: 'Yeah, the other thing I find with my GP for example, now she rang me, I have monthly blood test here and every 12 months you go to the GP and I go to the diabetic clinic, my diabetes is good so the doctor (GP) rang up and said, I think you're anaemic, I said well I've had these blood tests at the dialysis centre and nobody phoned up that I was anaemic' Patient ST10	'I think so, I think it [useful for GP's to be able to see the patients results, answers to some of these questions] would because most of this is in the community so it would be very, very useful for the GP's to be able to access all the information.' HCP04
3. Inner setting		
Compatibility of PROs and approaches to delivery of care in HD settings	Task-centred care versus patient-centred care: 'yes, you might be surrounded by them [unit staff] but they might not be asking questions, you might not feel you can ask questions. There might be aspects that you might not necessarily think it is worthwhile asking.' Patient J118	Task-centred care versus patient-centred care:  'we don't always see the bigger picture, we're so focused on getting that needle in to get dialysis, that we forget, oh my god, there's a person on the end of that arm' HCP12
		'in-centre, it's looking at the patient, home haemo it's looking at the person.' HCP08
		'I think the nurses have got time to get to know the patients to a certain extent as far as medically, their medication is involved. You know, how poorly they are, obviously what they need. Unfortunately, I don't think they have time to carry that a bit further' HCP02
		Continued

Anderson NE, et al. BMJ Open 2021;11:e052629. doi:10.1136/bmjopen-2021-052629

Table 3 Continued			<u> </u>
Key finding	Illustrative quotation		
PROs as part of a wider educational framework — 'the information loop'	Health literacy of patients: 'Talking about monthly QA reports—'and we all get these, telling us about our potassium, and somebody says to me, do you understand them? I say, I haven't got a clue, he says nor me, I says, all I know, when I go in there, they tell me that's okay, that's okay, I said but I haven't got a clue'.' Patient BA14	Implementation must be part of a wider framework of training, education and support: 'this will be exciting if implemented correctly, but there's a whole massive amount of work, it's not just this, it's everything else around it yeah, I think so.' HCP17	
		Staff education requirements: So I guess education would be vital, but they're about communication skills, they're about learning what matters in chronic disease management. And it would also be about, because that's burdensome, it's hugely draining to do it day in day out with a similar group of people. And you would need to put in day in day out with a similar group of people. And you would need to put in support, raising the education for them is one, raising awareness. But I also think if you are hearing people's symptoms, which are as I say some of them you can't resolve and you're hearing them day in day out, you need somewhere to offload to as well. So it's like, but building a good structure around what's needed. But that doesn't mean don't talk about them.' HCP05	
4. Characteristics of individuals			
Previous experience of using PROs Concept of PROs versus PREMs	Have you ever completed anything like these questionnaires before? 'No I don't think so.' Patient UV11, Patient BA14 'No I haven't.' Patient WX12 'I think I have, but I can't remember, it must have been some time agoI don't think there were as many questions as that one.' (KDQOL-SF) Patient DC15	'I mean I've used them in various research projectsAnd that's one of the reasons why I haven't routinely used them in clinical practice because I think they're fine for research, but I haven't found one that's hugely clinically, that I feel I'd really want to use.' HCP06	
Multidimensionality of ESKD and consequent challenges	Interviewer: Have you been asked to complete anything like that [exemplar PROs] before? Patient MN20: I've done questionnaires before, I think. Interviewer: Have you? What kind of questions did they ask? Were they similar ones? Patient MN20: Most of them have been in here about the staff and stuff about dialysis and how long I've been on it. It was similar.	'[PROMs & PREMs] I get confused and I think there's crossover and I find it quite difficult to draw a line between experience and outcome. Because for example, the experience of a patient. So, tiredness for example can be strongly affected by a patient experience. So, you have travelled six hours to get there or waited for your transport, your experience, it affects your tiredness which is—I think—I'm not sure always it's a useful distinction.' HCP12	
	"obviously the doctors can't cure that, they can't cure that, they can only cure your medical condition, they can't cure your mental condition so that's for you, but they can make it as well, so they give you the positivity to carry on.' Patient BA14 "it's most of the time that I get anxious with social situations because of my other medical problems. It's not just about my kidney problems and then dealing with the social aspect. It's my kidney problems, plus my other medical problems and then	Interviewer: Yeah. So do you think we should be measuring them (PROMs and PREMs) at the same time? HCP16: I think that they should be part of the same thing. I think that they should be seen so that we can pick apart whether people are happy with the should be seen so that we lay but also how that interplays with their health and their feelings and their symptoms so I think the two things overlap.	
	the social situation. I have to deal with my other medical problems before I can even contemplate going out with family or friendsor shopping and things like that.' Patient WX12	'If we can't do much about it, then it's not our problem, sort of thing. That's one of those barriers; I think there's the worry that it uncovers things that are uncomfortable to talk about' HCP15	
	'The main problem? [with dialysis] Social life. Absolutely, It's not just my social life; it's the wife's social life as well. She's like a nurse to me really. Without wife, I don't know where I'd be. I've got two lads but you can't rely on them to be here.' Patient YZ13	'Acknowledgement that there are aspects of care that do not fall within doctors 'remit' 'things that aren't necessarily medical, that may relate to social services or other things that are driving a symptom or feeling that relates more to social care, to a dietitian or other members of the team'.' HCP16	Open a
5. Process of implementation			

BMJ Open: first published as 10.1136/bmjopen-2021-052629 on 26 August 2021. Downloaded from http://bmjopen.bmj.com/ on September 15, 2021 at University of Worcester. Protected by copyright.

Table 3 Continued		
Key finding	Illustrative quotation	
Supporting the process of implementation  Barriers to effective implementation: time/attitude/IT problems	Importance of leadership and champions: 'Yeah, Yeah, I've helped a lot of people. When I used to go to look at their machines, because they send me first to look at the room and whether it can be done, they didn't even know I was on dialysis. They'd look at me and say you seem to know a lot about this'. I said, 'yeah, because I'm a dialysis patient'.' Patient YZ13 'They [Doctors] haven't got time anymore. We all know that, but it's nice to not be rushed along and ignored.' Patient MN20 'It does annoy me when we have problems with logging in and passwords.' Patient	Importance of leadership and champions: 'Time, resources, you know, if someone's not here, say, if it was me implementing it, if I'm not here, I'm thinking, will it get done? It's as simple as that.' HCP17 'You might need to bring somebody else in from outside, yeah but that runs its own complications so what's the answer, a patient representative might be an answer, somebody who knows dialysis.' HCP17
Facilitators to effective implementation: how PROs might deliver a relative advantage over current systems of care delivery	WX12  Acts as a communication tool:  'Yeah, yeah, you know, if you had a form to fill in, you're divorced from it because obviously within our human nature we always, we don't want to look vulnerable, we don't want to look vulnerable, if the doctors say, you might be feeling sick, and you think, well I only get it now and again, to yourself, this is, so you don't mention it but if you mentioned it, he or she can make a diagnosis on that,'	Bottom-up approach:  'Often there are new things that are introduced and when you've just got to do it attitude. Now that just gets peoples backs up to start withhave a proper process in place to prepare people.' HCP07  'So it has to be easy access for the patient. It's pointless having something they can't actually get to and that's scary or frustrating to get onto, to log on or something, yeah.' HCP05
	'I couldn't seem to settle in, i.e. couldn't communicate with the nurses, me as a person, I don't communicate very well.' Patient QR09 Help target the consultation: save time.	Could reduce workload: I find it really interesting how people would say that this is an increase in workload, when actually this is things that you need to be looking at anyway. For me this is nothing out of what I'm already looking at in every patient and of course it will be an increase in workload if you don't look at them.' HCP17
	'Probabiy save your doctor from doing some of the work as wellAs I say, if I'm not giving information that I need, we're not getting anywhere, are we?' Patient AB01 giving information that I need, we're got the information on that at the same time, 'If we've got monthly bloods and we've got the information on that at the same time, they can look at that [ePRO] instead of looking at the computer and seeing what's really	Potentially time saving: 1 think the PROMs, certainly one is useful when they fill them in but quite often they haven't filled them in and it's then sometimes difficult to ascertain have they not filled them in because they have got symptoms but they just aren't necessarily engaging or thinking oh therefore I will fill this in or whether they haven't filled it in 'cause they're fine. But then at the same time it's quite easy
	going on with that person' Patient AB01 'Even if that doctor is reading that one-on-one, he can look at thiseven if it's on a computer, he can look at it and say, 'He's got a problem with that area. Let's go and deal with that'.' Patient AB01	to ask a patient and say, 'Have you not filled this in?', because actually they're fine and then they'll say, 'Yes, I'm fine. There's nothing to worry about', sort of thing and then in a way you can think well I can, I don't necessarily need to give you targeted questions 'cause you've already got the opportunity to do that. Sometimes it then speeds things up.' HCP06
	'These questionnaires are good as well because a couple of symptoms cropped up that I do get but that I forgot is related to everything. I thought, 'Oh, that's why I get that then. Oh, that's why I get that'.' Patient WX12	
ESKD, end-stage kidney disease; GP, c	ESKD, end-stage kidney disease; GP, general practitioner; HCP, healthcare professional; HD, haemodialysis; IT, information technology; KDQOL-SF, Kidney Disease Quality of Life Short Form; PREM, patient-reported	KDQOL-SF, Kidney Disease Quality of Life Short Form; PREM, patient-reported

experience measure; PRO, patient-reported outcome; PROM, patient-reported outcome measure.

BMJ Open: first published as 10.1136/bmjopen-2021-052629 on 26 August 2021. Downloaded from http://bmjopen.bmj.com/ on September 15, 2021 at University of Worcester. Protected by copyright.

8

Table 4 Practical consideral	Practical considerations and illustrative direct quotes	
Practical considerations	Key findings	
	Patient participants	HCP participants
Frequency (to allow for accurate recall)	Wide variation of responses from 1 week to 12 months. Agreement that it needed to match recall while allowing for treatment responses. Several patients would complete as frequently as asked—demonstrating no preference.	Wide variation of responses from, as required to 12 months. Focus on practicality, that is, how often they thought patients would complete and time burden rather than sensitivity to changes and recall. Before routine clinic visit was a popular response.
Timing (in relation to dialysis cycle)	Some patients wanted to complete during dialysis but noted this could be practically difficult, particularly if their access was in dominant arm. Most did not want to complete immediately after dialysis, the majority requiring some recovery time.	'Horses for courses' HCP11 meaning that people are different and will need different things. In terms of timing, some will need a short amount of time to complete, others will need longer.
		Options, in centre before or during session or patient's choice at home (need time frame for completion? ie, within 5-day window). General agreement that straight after dialysis patients are very fatigued, so not optimum time for completion. Effects of cognitive status on concentration levels—ability to partially complete and come back later, recall bias will be relevant. Need to consider are you asking about today, last 2 weeks, last month, when designing a tool.
Setting of completion (home/ in centre)	Some favoured completion in centre, others preferred to complete at home, particularly if carer assistance required.	Patients needed options (home/unit)—some patients need assistance so carers could help (unlikely nurses would have time). It was suggested better returns if encouraged to complete at unit: at home patients are 'distracted by life'.  'Will responses be different if completing at home—does that matter? 'either way, you're gonna get the reality of their life, so perhaps it doesn't matter'. HCP05 Lack of privacy in centre noted by number of respondents.
Mode of capture	Varied responses—digital, paper or no preference. Proponents of digital capture displayed no obvious preference for choice of device. Only one patient had no access to a digital device at home.  Preference for paper often reflected lack of confidence in ability to complete digitally, a number said they would need assistance to complete electronically.  'I feel like my confidence is down and that needs to build back up again before I use the computer.' Patient CD02	Advantages of electronic collection raised (real-time review, less admin, less likely to lose returns, easier to track responses, to review responses/ feedback) but option of paper needs to be available, as some patients would be unable to complete digitally, and who would provide this assistance? Some pondered that current digital resources, that is, PatientView, are not widely used. IT systems require resource for infrastructure, upkeep and training.
Readability	No jargon or medical terms—got to be easy to read and understand. Guidance around more complex constructs.  Availability of measure in other languages.  You may find you need to print them in their own Urdu or whatever, so that they do understand them. And that has to be very careful that the question doesn't get lost in the translation.' Patient MN07	Simple and clear rating scales for staff undertaking interpretation.  Need to be culturally sensitive/valid and available in languages other than English.

BMJ Open: first published as 10.1136/bmjopen-2021-052629 on 26 August 2021. Downloaded from http://bmjopen.bmj.com/ on September 15, 2021 at University of Worcester. Protected by copyright.

Table 4 Continued		
Practical considerations	Key findings	
	Patient participants	HCP participants
Length of questionnaire	Generally, length was not an issue, provided patients could see a purpose to completion. There was a dislike of repetitive questions. Potential time burden of lengthy questionnaires, seen as an inconvenience for carers. 'So the other question I was going to ask was were you put off by the length of some of those questionnaires?' Interviewee: 'No I wasn't, no, you know I'd put aside the time to do it so no I wasn't, I could see the point of them.' Patient UV11	Consensus that the shorter the questionnaire, the better. Some commented that current validated PROs were much too lengthy.
Form of feedback	No overall preference: could be letter, email or discussion. Most happy to use graphical data. However, it is important that timely feedback given and PRO completion 'not just a tick box exercise'. Some patients wanted carers involved in feedback process. 'Because I don't do emails and sometimes my eyesight, I can't able to read. Yeah. I prefer in person.' Patient GHO4  The need for timely feedback was made: Interviewer: So you'd want to see some sort of feedback within two	Consensus that electronic feedback is ideal. Responses outlined in letter to patient or face to face in clinic to allow 'probing' —but this requires resource. Agreement that longitudinal data would be advantageous to see trends—preference for graphical rather than tabular form—but scales need to be well thought through, 0–3 not considered 'sensitive' enough to be able to show changes—preference for EQ-5D thermometer scale… 'but a 'Blunt tool'—good clinician should pick up sensitive changes before PROs would.' HCP11 No time to read lots of free text.
	weeks. Interviewee: 'Two weeks and they sort it out. Not leave it for months and months and years, no good at all.' Patient KL06 'As well as giving helpful information to help you manage your condition, it would also be useful to have information about what	
	causes certain trings in order to put your rilling at rest, if you know what I mean?' Patient CD02	
Setting of feedback	Currently most consultations take place while the patient is dialysing. Patients gave mixed responses to the wish to be seen in private, most did not want additional or extended visits at the dialysis unit and seemed resigned to being seen in open bays.	If medical staff were providing feedback in person, pragmatically best to do this in clinic, it was acknowledged this feedback can take place at the bedside during dialysis but participants noted this may affect the quality and content of the discussion.
Who provides feedback	No overall preference, but one patient felt more comfortable talking to nursing staff.	Variation on responses—some thought medical staff (but concerns raised around time and workload), others thought nurses (some anxiety regarding time constraints and knowledge/experience of junior nursing staff to know how to manage symptoms or issues raised by PROs).  'Need clear process for review and feedback—'can't have 6 nurses going back to patient to discuss responses'.' HCP16

EQ-5D, EuroQol-5 Dimension; HCP, healthcare professional; IT, information technology; PRO, patient-related outcome.

BMJ Open: first published as 10.1136/bmjopen-2021-052629 on 26 August 2021. Downloaded from http://bmjopen.bmj.com/ on September 15, 2021 at University of Worcester. Protected by copyright.

and holistic in their approach to care. Analysis of patient and HCP data suggested that time constraints were the major reason for a task-based approach in centre with both patients and staff exhibiting a desire to complete dialysis sessions with as little impediment as possible. Correspondingly, most in-centre patients did not feel staff had time to have long discussions and some suggested PROs might help rectify this. There was no discernible variation in the views of the HHD cohort on the practicalities of PRO collection.

# Part of a wider framework: the 'information loop', the role of PROs in addressing training needs and health literacy

HCP data analysis highlighted the importance of education, training and support for successful implementation. It was indicated that while medical staff needed training in PRO interpretation, such as rating scales, nurses might need a broader programme on use of PROs as well as associated chronic disease management. There was disparity indicated in the health literacy of the patient group; some HHD patients appeared expert in their illness and treatment, while some in-centre patients appeared less confident in their knowledge.

# Characteristics of individuals: factors associated with individuals involved in implementation

### Previous experience of using PROs

Patients expressed an overall lack of awareness and experience of PROs. Many had completed annual PREMs but highlighted a lack of feedback or action. Some patients expressed general anxiety about questionnaire completion, linked to their experience of externally administered questionnaires for other agencies: for example, Personal Independence Payment surveys assessing entitlement to extra costs associated with long-term ill health or disability. When reviewing the example PROs, it was noted that some patients, particularly those from minority ethnic backgrounds, flagged the potential difficulty around asking about sensitive issues such as sexual function. While the participants themselves were happy to discuss such issues, they recognised that not all patients might be.

All nephrologists interviewed had experience of using PROs in research settings, but none had regularly and systematically collected PROs in routine care. PRO use in any setting was largely a new concept for nursing staff.

There was a confusion around the concepts of PROs versus PREMs, expressed by both patients and HCPs. Participants found it hard to distinguish experience of care from outcomes and used terms interchangeably.

### Multidimensional aspects of ESKD and consequent challenges

Many of the patients in the study had multiple comorbidities and associated symptoms, reflective of the wider HD population. Patients indicated that it was often hard to know which symptoms related to their ESKD and/or treatment, and which were associated with other diseases or advancing age; leading to anxiety about what to raise

during a consultation. It was suggested that PRO data review and feedback gave a chance to discuss symptoms and potential causes, thereby potentially providing reassurance. However, some clinicians thought it was outside their role to manage non-nephrology-related outcomes presented by PROs and that it would be difficult to disentangle several, possibly unrelated, symptoms. They feared focusing on symptoms that were not currently being experienced or intractable could cause frustration or anxiety for themselves and the patients. Some patients gave a contrasting opinion, revealing the chance to be heard, even without a solution, was often sufficient to maintain the patient—clinician relationship. There was also concern that an over-reliance on PROs could result in a distraction from other important clinical issues.

The experience of life on dialysis was highly varied, with some participants exhibiting signs of depression, anger or acceptance, as well as reporting multiple symptoms.

### The process of implementation Supporting the process of implementation

The analysis identified leadership, the identification of champions and a 'bottom up' approach to communication and shared solutions among both patients and clinicians as key factors supporting implementation. All participants emphasised the importance of support during completion; however, patients highlighted this need not always be delivered by healthcare staff. Peer-topeer support and non-clinical champions, that is, administrative staff, might assist. HCPs felt a comprehensive launch was important and that individual roles should be clear. They reflected that senior members of the clinical team would be opinion leaders, and any change agents would need to understand the dialysis setting. Evaluation and reflection were important process components to recognise and deal with any unintended consequences.

# Overarching themes: barriers and facilitators to effective implementation

Across all CFIR constructs, analysis identified potential barriers and facilitators to the introduction of PROs.

### Potential barriers

Nephrologists cited a lack of evidence base supporting the use of PROs in routine kidney care and were concerned regarding the risk of overmedicalising the patient experience. There were perceived time barriers for staff, that is, workflow interruptions, additional obligations caused by PROs; with nurses perceiving quality time with patients in centre as limited. HCP participants argued that nursing documentation had lessened available time, as it often required recording on digital devices away from the bedside. They feared patients were being overburdened by questionnaires, particularly the less health literate.

In contrast, patients were often already aware of the complications associated with ESKD and HD. Many had achieved a degree of acceptance and some were reassured that the symptoms were expected and not something new

to deal with. Frustration would only arise if, having taken time to complete the questionnaires, no action was taken. Both groups agreed that IT issues, that is, inability to log in, no Wi-Fi, could be a barrier.

### Potential facilitators

Several HCPs considered how PROs might work to deliver a relative advantage over current systems to support more patient-centred care. Participants felt PROs could be a communication tool-acting like a 'tin opener'; but requiring that responses be carefully probed, highlighting that this required appropriate skills and training. Others saw the measures as an aide-mémoire which could help target the consultation and even save time; as could the possibility of remote management of care using ePROs. Perhaps, most importantly, PROs were seen by both patients and HCPs as a way to get to know the patients and hence deliver more meaningful care.

### DISCUSSION

There is a growing body of published, peer-reviewed literature exploring the experiences of both kidney patients and multidisciplinary kidney HCPs with ePROs. 13 17 23 26 27 52 Previous studies have included non-dialysis-dependent CKD and peritoneal dialysis populations, <sup>17</sup> 23 <sup>27</sup> evaluating existing ePROs and associated delivery systems. This paper adds to the corpus by using semistructured interviews to gain rich data to inform and optimise future ePRO implementation in an HD population naïve to ePRO collection and clinicians unused to routine and systematic ePRO use.

The key findings of this study are that while patients and HCPs support the concept of PROs, further evidence of their potential benefit is required for effective implementation. It emphasises that any system should be flexible and measure what matters most to patients. Most importantly, the data collected should be acted on. There was a general lack of awareness and experience of PROs particularly among patients and nurses, with concern among the HCPs that PRO capture may highlight issues they might have neither the experience nor resources to manage. Therefore, a comprehensive implementation strategy is required to support any delivery, which involves strong leadership, patient and clinician involvement and ongoing training.

This study highlighted the importance of getting 'buy in', that is, gaining acceptability, from these stakeholders. This could be achieved by demonstrating evidence on their potential benefits thereby increasing trust to warrant practice change. Clinicians particularly questioned whether positive effects on survival, reported QoL, patient-clinician communications and cost efficiencies demonstrated in oncology<sup>29</sup> 53–55 could be replicated in HD settings.

The body of evidence around ePROs in nephrology is emerging. Studies from North America demonstrate the feasibility of electronic capture of PROs in HD<sup>1924</sup> and an

Australian pilot study is currently exploring the feasibility and acceptability of ePRO capture and feedback among patients receiving HD in the Symptom Monitoring With Feedback Trial.<sup>20</sup> In advanced CKD populations, the Renal Electronic Patient Reported Outcome Measures (RePROM) study is piloting the use of an ePRO for remote symptom monitoring in the UK, 56 while the Ambu-Flex telePRO system is used to manage renal follow-up in Denmark.<sup>25</sup> Aiyegbusi *et al*<sup>17</sup> explored key stakeholder perspectives on the use of PROs in these predialysis patients and their findings are consistent with this study, particularly regarding potential benefits and administrative aspects; suggesting PRO data collection early in the patient pathway can be instituted and continue as illness advances through to renal replacement therapy or even conservative care.

A review and synthesis of evidence is currently being undertaken to investigate how PROs might work to enhance patient-centred care in renal settings, to offer strategy and guidance at individual and aggregate levels of decision-making.<sup>57</sup> For effective multiple uses of data, implementation needs to be viewed within the context of complex data linkage and accessibility issues. Studies in the UK and Australia are currently exploring and testing such linkage of symptoms and QoL data to the Australia and New Zealand Dialysis and Transplant Registry and UK Renal Registry. 20 22 58

However, the purpose of data collection must be clear. Participants in this study confused the concepts of PROs versus PREMs, understandable given that experience of undertaking HD is intricately linked to both HRQoL and symptoms. The integrated use of both measures, side by side, warrants further investigation. Anxieties about purpose and data sharing could affect patient engagement; clear communication of roles and expectations should be undertaken.

While guidance exists on what outcomes to measure in research<sup>5</sup> and routine practice<sup>9</sup> this has not necessarily been centred on routine capture and feedback to guide individual care. Consequently, it is not clear which measure(s) should be used to capture data in a nonburdensome way, while providing sufficient measurement properties to support both single patient monitoring and aggregation of data where required, meaning further enquiry is needed.

The general lack of awareness and experience of PROs and concern that PRO capture may highlight issues that HCPs should not or cannot deal with, leads to a significant finding that PRO implementation must sit within a broader educational framework. PROs could be used to support wider initiatives and training, especially in the nursing group, who can then cascade information and self-management skills to patients, thereby increasing overall patient health literacy. This could be considered as closing an 'information loop'. There is already evidence that patient education is associated with better patient outcomes<sup>59</sup> and new strategies and quality improvement programmes exist such as Shared HD, a UK programme aiming to support patients receiving in-centre HD to be more independent and confident in participating in aspects of their own care. <sup>60</sup> Potential barriers are cost and resources, but increasingly, accredited online learning facilities are available. However, it is acknowledged, staff in this study indicated a preference for face-to-face training. Education and training on PROs would be needed for all stakeholders.

This study identified time and workflow interruptions as key barriers to implementation. Rotenstein *et al*<sup>51</sup> found that following initiation of routine PRO collection in surgical settings, such concerns shifted as clinicians became comfortable with new processes. There was even a suggestion that PROs could enhance physician satisfaction and prevent 'burnout'. <sup>61</sup> Tong *et al*<sup>62</sup> interviewed the nephrologists, who also identified resource constraints and uncertainties in how to prioritise, measure and manage a range of competing comorbidities and broader QoL outcomes in a clinical setting that is technically demanding and traditionally focused on biochemical factors; findings mirrored by this study. Such anxieties will need addressing.

During the SARS-CoV-2 pandemic, data from the UK Renal Registry showed that patients undergoing HD experience a relative risk of mortality of 45.5% compared with the general population. <sup>62</sup> This vulnerable population has been unable to effectively shield, requiring regular dialysis treatment with associated risks around shared transport and waiting areas. Various strategies have been employed to reduce risks<sup>63</sup> but new ways of care delivery were required. The pandemic has irrevocably changed healthcare, with increased use of virtual services<sup>64</sup> and remote clinic visits. The addition of ePROs to readily available biomedical data means that clinicians could more effectively deliver patient-centred care without the necessity of the patient being physically present. This study also suggests that remote symptom monitoring could offer patients the safety and confidence to dialyse at home and arguably ePROs could assist the HHD service in maintaining its patient-centred approach while serving ever increasing numbers.

There are limitations to this study. Participants needed to be English speakers; this could affect transferability of findings. Views of carers were not specifically sought but their influence and importance were clearly identified by patients, suggesting further research targeting this group is warranted. Critically, data collection took place before SARS-COV-2 pandemic and experiences and perceptions around digital data capture and new approaches to healthcare delivery may well have shifted.

To conclude, the SARs-COV-19 pandemic has caused an irreversible shift in healthcare delivery, with increased use of digital communication and assessment. While the nephrology community, both patients and HCPs, are largely supportive of the concept of ePROs, there remain caveats to their routine and systematic use. Stakeholders need to be convinced by empirical evidence, considering the best available measures and methodological

considerations. By exploring the experiences, views and perceptions of major stakeholders, this study identified key factors at organisational and individual levels which would assist effective implementation of ePROs. Further research will then be required to evaluate any subsequent ePRO interventions to empirically demonstrate the impact and benefit of their use to the dialysis community.

### **Author affiliations**

<sup>1</sup>Research and Development, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK

<sup>2</sup>Department of Renal Medicine, University Hospitals Birmingham NHS Foundation Trust. Birmingham. UK

<sup>3</sup>Centre for Patient Reported Outcomes Research, Institute of Applied Health Research, University of Birmingham, Birmingham, UK

<sup>4</sup>NIHR SMRC, University of Birmingham and University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK

<sup>5</sup>NIHR Birmingham Biomedical Research Centre, University of Birmingham and University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK <sup>6</sup>Centre for Regulatory Science and Innovation, Birmingham Health Partners, Birmingham, UK

<sup>7</sup>NIHR Applied Research Collaboration West Midlands, University of Birmingham, Birmingham, UK

<sup>8</sup>School of Allied Health and Community, University of Worcester, Worcester, UK

Twitter Nicola Elzabeth Anderson @neanderson100 and Christel McMullan @ christel\_uob

Acknowledgements PROM-HD PPI Group, Renal Research Patient Advisory Group, Queen Elizabeth Hospital Kidney Patients Association (QEKPA).

Contributors NEA, CMcM, MC, MD, PC, OLA, DK: substantial contribution to the conception and design of the study. NEA: data collection. NEA, CMcM, DK: analysis and interpretation of data for the work. NEA, CMcM, MC, MD, PC, OLA, DK: drafting and revising the work critically for important intellectual content and final approval of version to be published and agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Funding (Nicola Anderson, Clinical Doctoral Research Fellow, Grant Reference ICA-CDRF-2018-04-ST2-027) is funded by Health Education England (HEE) / National Institute for Health Research (NIHR) for this research project.

**Disclaimer** The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. The study sponsor and funders have no role in study design, including collection, management, analysis and interpretation of data; writing of the report and the decision to submit the report for publication.

Competing interests MC is an NIHR senior investigator and receives funding from the NIHR Birmingham Biomedical Research Centre, the NIHR Surgical Reconstruction and Microbiology Research Centre and NIHR Applied Research Collaboration West Midlands at the University of Birmingham and University Hospitals Birmingham NHS Foundation Trust, Health Data Research UK, Innovate UK (part of UK Research and Innovation), Macmillan Cancer Support, UCB Pharma and GSK. MC has received personal fees from Astellas, Takeda, Merck, Daiichi Sankyo, Glaukos, GSK and the Patient-Centered Outcomes Research Institute (PCORI) outside the submitted work. DK reports grants from Macmillan Cancer Support, Innovate UK, the NIHR, NIHR Birmingham Biomedical Research Centre and NIHR SRMRC at the University of Birmingham and University Hospitals Birmingham NHS Foundation Trust, and personal fees from Merck and GSK outside the submitted work. OLA is funded by the NIHR Birmingham Biomedical Research Centre and declares personal fees from Gilead Sciences and GSK.

Patient consent for publication Not required.

Ethics approval Ethics approval was issued on 13 September 2017 (Ref No: 17/ WA/0281) by Wales 7 Ethics Committee.

Provenance and peer review Not commissioned; externally peer reviewed.

**Data availability statement** Data are available upon reasonable request. Deidentified data may be available upon reasonable request via the corresponding author (ORCID 0000-0002-0614-3198). Protocol available doi:10.1136/bmjopen-2018-021532.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

### **ORCID iDs**

Nicola Elzabeth Anderson http://orcid.org/0000-0002-0614-3198 Christel McMullan http://orcid.org/0000-0002-0878-1513 Melanie Calvert http://orcid.org/0000-0002-1856-837X Derek Kyte http://orcid.org/0000-0002-7679-6741

### REFERENCES

- 1 Bikbov B, Purcell CA, Levey AS, et al. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the global burden of disease study 2017. The Lancet 2020;395:709–33.
- 2 Almutary H, Bonner A, Douglas C. Symptom burden in chronic kidney disease: a review of recent literature. *J Ren Care* 2013;39:140–50.
- 3 Abdel-Kader K, Unruh ML, Weisbord SD. Symptom burden, depression, and quality of life in chronic and end-stage kidney disease. Clin J Am Soc Nephrol 2009;4:1057–64.
- 4 KDIGO. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International Supplements 2013;3:1–150.
- 5 Evangelidis N, Tong A, Manns B, et al. Developing a set of core outcomes for trials in hemodialysis: an international Delphi survey. American Journal of Kidney Diseases 2017;70:464–75.
- 6 Tong A, Manns B, Hemmelgarn B, et al. Establishing core outcome domains in hemodialysis: report of the standardized outcomes in Nephrology-Hemodialysis (SONG-HD) consensus workshop. Am J Kidney Dis 2017;69:97–107.
- 7 Viecelli AK, Tong A, O'Lone E, et al. Report of the standardized outcomes in nephrology-hemodialysis (SONG-HD) consensus workshop on establishing a core outcome measure for hemodialysis vascular access. Am J Kidney Dis 2018;71:Pages 690–700.
- 8 Urquhart-Secord R, Craig JC, Hemmelgarn B, et al. Patient and caregiver priorities for outcomes in hemodialysis: an international nominal group technique study. Am J Kidney Dis 2016;68:444–54.
- 9 Verberne WR, Das-Gupta Z, Allegretti AS, et al. Development of an international standard set of value-based outcome measures for patients with chronic kidney disease: a report of the International Consortium for health outcomes measurement (ICHOM) CKD Working group. Am J Kidney Dis 2019;73:372–84.
- Working group. Am J Kidney Dis 2019;73:372–84.

  10 International Consortium for Health Outcomes Measurement (ICHOM). Chronic kidney disease: data collection reference guide. ICHOM; 2017 OCT 25th 2017. contract No.: version 1.0, 2021. Available: https://www.ichom.org/wp-content/uploads/2020/02/ICHOM-Chronic-Kidney-Disease-Reference-Guide-20171025-1.00. pdf
- 11 FDA. Guidance for industry. Patient reported outcomes measures: Use in medical product development to support labeling claims. Docket No:FDA-2006-D-0362, 2009. Available: https://www.fda.gov/media/77832/download
- 12 UK Renal Assocation & Kidney Care UK. Patient reported experience of kidney care in the UK 2020, 2021. Available: https://www.kidneycareuk.org/news-and-campaigns/prem/#:~:text=PREM% 20stands%20for%20Patient%20Reported%20Experience% 20Measures.%20The,improvement%20can%20be%20made% 20from%20a%20patient%20perspective
- 13 Smith V, Wise K. Evaluating nurses' action outcomes and exploring their perspectives of implementing the POS-S (Renal) assessment tool for haemodialysis patients. *Renal Society of Australasia Journal* 2017;13:14–21.

- 14 Schick-Makaroff K, Mharapara P. Use of electronic patient-reported outcomes in the care of patients with kidney failure. Nephrol Nurs J 2020;47:465–72.
- 15 Aiyegbusi OL, Kyte D, Cockwell P, et al. Using patient-reported outcome measures (PROMs) to promote quality of care and safety in the management of patients with advanced chronic kidney disease (PRO-trACK project): a mixed-methods project protocol. BMJ Open 2017;7:e016687.
- 16 Aiyegbusi OL, Kyte D, Cockwell P, et al. Development and usability testing of an electronic patient-reported outcome measure (ePROM) system for patients with advanced chronic kidney disease. Comput Biol Med 2018;101:120–7.
- 17 Aiyegbusi OL, Kyte D, Cockwell P, et al. Patient and clinician perspectives on electronic patient-reported outcome measures in the management of advanced CKD: a qualitative study. Am J Kidney Dis 2019;74:pages 167–78.
- 18 Kyte D, Anderson N, Auti R, et al. Development of an electronic patient-reported outcome measure (ePROM) system to aid the management of patients with advanced chronic kidney disease. J Patient Rep Outcomes 2020;4:55.
- 19 Gabbard J, McLouth CJ, Brenes G, et al. Rapid electronic capturing of patient-reported outcome measures in older adults with endstage renal disease: a feasibility study. Am J Hosp Palliat Care 2021;38:432-440.
- 20 Viecelli A, Dansie K, McDonald S, et al. Symptom monitoring with feedback trial (swift) pilot to explore the feasibility and acceptability of electronic patient reported outcome measures (e-proms) data capture and feedback. Nephrology Dialysis Transplantation 2020:35:iii137.
- 21 Breckenridge K, Bekker HL, Gibbons E, et al. How to routinely collect data on patient-reported outcome and experience measures in renal registries in Europe: an expert consensus meeting. Nephrol Dial Transplant 2015;30:1605–14.
- 22 Van Der Veer SN, Ercia A, Caskey FJ, et al. Developing an intervention to implement electronic patient-reported outcomes in renal services in the UK. Stud Health Technol Inform 2020;270:936–40.
- 23 Schick-Makaroff K, Molzahn AE. Evaluation of real-time use of electronic patient-reported outcome data by nurses with patients in home dialysis clinics. *BMC Health Serv Res* 2017;17:439.
- 24 Schick-Makaroff K, Molzahn A. Strategies to use tablet computers for collection of electronic patient-reported outcomes. *Health Qual Life Outcomes* 2015;13:2.
- 25 Schougaard LMV, Larsen LP, Jessen A, et al. AmbuFlex: tele-patient-reported outcomes (telePRO) as the basis for follow-up in chronic and malignant diseases. Qual Life Res 2016;25:525–34.
- 26 Trillingsgaard C NBK, Hjollund NH, Lomborg K. Use of patient-reported outcomes in outpatient settings as a means of patient involvement and self-management support a qualitative study of the patient perspective. European Journal for Patient-Centred Healthcare 2016;4:359–67.
- 27 Schick-Makaroff K, Tate K, Molzahn A. Use of electronic patient reported outcomes in clinical nephrology practice: a qualitative pilot study. Can J Kidney Health Dis 2019;6:2054358119879451.
- 28 Yang Y, Chen H, Qazi H, et al. Intervention and evaluation of mobile health technologies in management of patients undergoing chronic dialysis: Scoping review. JMIR Mhealth Uhealth 2020;8:e15549.
- 29 Basch E, Deal AM, Dueck AC, et al. Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA 2017;318:197–8.
- 30 Lizée T, Basch E, Trémolières P, et al. Cost-Effectiveness of webbased patient-reported outcome surveillance in patients with lung cancer. J Thorac Oncol 2019;14:1012–21.
- 31 UK Renal Association. Electronic patient-reported outcomes (ePROs) for the kidney patient community 2020. available at. Available: https://www.youtubecom/watch?v=iQ0mOVee\_dg&feature=youtube
- 32 Kelly LM, Cordeiro M. Three principles of pragmatism for research on organizational processes. *Method Innov* 2020;13:205979912093724.
- 33 Yvonne Feilzer M, Feilzer YM. Doing mixed methods research Pragmatically: implications for the rediscovery of pragmatism as a research paradigm. J Mix Methods Res 2010;4:6–16.
- 34 Kaushik V, Walsh CA. Pragmatism as a research paradigm and its implications for social work research. *Soc Sci* 2019;8:255.
- 35 Damschroder LJ, Aron DC, Keith RE, et al. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. *Implement Sci* 2009;4:50.
- 36 Sandelowski M. Whatever happened to qualitative description? Res Nurs Health 2000;23:334–40.
- 37 Sandelowski M. What's in a name? qualitative description revisited. Res Nurs Health 2010;33:77–84.

- 38 Kim H, Sefcik JS, Bradway C. Characteristics of qualitative descriptive studies: a systematic review. Res Nurs Health 2017:40:23–42.
- 39 Neergaard MA, Olesen F, Andersen RS, et al. Qualitative description the poor cousin of health research? BMC Med Res Methodol 2009;9:52.
- 40 Anderson NE, Calvert M, Cockwell P, et al. Using patient-reported outcome measures (PROMs) to promote quality of care in the management of patients with established kidney disease requiring treatment with haemodialysis in the UK (PROM-HD): a qualitative study protocol. BMJ Open 2018;8:e021532.
- 41 Etikan I. Comparison of convenience sampling and purposive sampling. American Journal of Theoretical and Applied Statistics 2016:5:1.
- 42 Standardised Outcomes in Nephrology (SONG). The song Handbook. Version 1. Sydney, Australia, 2017. Available: songinitiative.org/ reports-and-publications/
- 43 Hays R D KJD, Mapes DL, Coons SJ, et al. Kidney disease quality of life short form (KDQOL-SF): a manual for use and scoring. in: Rand, editor. Santa Monica, CA: Rand, 1997. https://www.rand.org/ content/dam/rand/pubs/papers/2006/P7994.pdf
- 44 Hays RD, Kallich JD, Mapes DL, et al. Development of the kidney disease quality of life (KDQOL) instrument. Qual Life Res 1994:3:329–38.
- 45 Pos-pal.org. Pos palliative care outcome scale, 2017. Available: https://pos-pal.org/maix/ipos-renal-in-english.php
- 46 Braun V, Clarke V. Can I use TA? Should I use TA? Should I not use TA? Comparing reflexive thematic analysis and other patternbased qualitative analytic approaches. Couns Psychother Res 2021;21:37–47.
- 47 van Oers HA, Teela L, Schepers SA, et al. A retrospective assessment of the KLIK PROM portal implementation using the consolidated framework for implementation research (CFIR). Qual Life Res 2020:2.
- 48 Birt L, Scott S, Cavers D, et al. Member checking: a tool to enhance Trustworthiness or merely a NOD to validation? Qual Health Res 2016;26:1802-1811.
- 49 Kerr C, Nixon A, Wild D. Assessing and demonstrating data saturation in qualitative inquiry supporting patient-reported outcomes research. *Expert Rev Pharmacoecon Outcomes Res* 2010;10:269–81.
- 50 UK Renal Registry. Uk renal registry 22nd annual report data to 31/12/2018,. Bristol, United Kingdom, 2020. Available: https://renal. org/audit-research/22nd-annual-report-data-31122018
- 51 Coulter A. Measuring what matters to patients. BMJ 2017;356:j816.

- 52 Tong A, Winkelmayer WC, Wheeler DC, et al. Nephrologists' perspectives on defining and applying patient-centered outcomes in hemodialysis. *Clin J Am Soc Nephrol* 2017;12:454–66.
- 53 Denis F, Basch EM, Lethrosne C, et al. Randomized trial comparing a web-mediated follow-up via patient-reported outcomes (pro) vs. routine surveillance in lung cancer patients: final results. *Journal of Clinical Oncology* 2018;36:6500.
- 54 Denis F, Basch E, Septans A-L, et al. Two-Year survival comparing web-based symptom monitoring vs routine surveillance following treatment for lung cancer. *JAMA* 2019;321:306–7.
- 55 Greenhalgh J, Abhyankar P, McCluskey S, Takeuchi E, et al. How do doctors refer to patient-reported outcome measures (PROMs) in oncology consultations? Qual Life Res 2013;22:939–50.
- 56 Kyte D, Bishop J, Brettell E, et al. Use of an electronic patient-reported outcome measure in the management of patients with advanced chronic kidney disease: the RePROM pilot trial protocol. BMJ Open 2018;8:e026080.
- 57 Schick-Makaroff K, Thummapol O, Thompson S, et al. Strategies for incorporating patient-reported outcomes in the care of people with chronic kidney disease (pro kidney): a protocol for a realist synthesis. Syst Rev 2019;8:20.
- 58 Morton RL, Lioufas N, Dansie K. Patient reported outcome measures in Australian and New Zealand renal units: an anzdata survey of current practice. *Nephrology* 2019;23:32.
- 59 Narva AS, Norton JM, Boulware LE. Educating patients about CKD: the path to self-management and patient-centered care. Clin J Am Soc Nephrol 2016;11:694–703.
- 60 Wilkie M, Barnes T. Shared hemodialysis care: increasing patient involvement in center-based dialysis. Clin J Am Soc Nephrol 2019;14:1402–4.
- 61 Rotenstein LS, Huckman RS, Wagle NW. Making patients and doctors Happier — the potential of patient-reported outcomes. N Engl J Med Overseas Ed 2017;377:1309–12.
- 62 Savino M, Casula A, Santhakumaran S, et al. Sociodemographic features and mortality of individuals on haemodialysis treatment who test positive for SARS-CoV-2: a UK renal registry data analysis. PLoS One 2020;15:e0241263.
- 63 Roper T, Kumar N, Lewis-Morris T, et al. Delivering dialysis during the COVID-19 outbreak: strategies and outcomes. Kidney Int Rep 2020;5:1090–4.
- 64 Hull SA, Rajabzadeh V, Thomas N, et al. Do virtual renal clinics improve access to kidney care? A preliminary impact evaluation of a virtual clinic in East London. *BMC Nephrol* 2020;21:10.
- 65 Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373–83.

### **PROM-HD Study**

Using patient reported outcome measures (PROMs) to promote quality of care and safety in the management of patients with established kidney disease requiring treatment with haemodialysis

### **Topic Guide - Patient Participant Interviews**

### **Research Objectives**

To explore the feasibility of using routine PROM assessment to aid the management of patients with established renal failure undergoing HD

### **Respondent Profile**

18 years or over, patients who are receiving renal replacement therapy in the form of HD, who meet the study inclusion/exclusion criteria

### Logistics

Face-to face interviews: place, date, and time (start and end) of the interviews to be recorded.

Telephone interviews: write the name, title, telephone number of the respondent and record data and time (start and end time) of interview.

### Introduction

Introduce self as a Nurse Researcher but explain that whilst I have a nursing background I am not part of their direct healthcare team, so please feel to talk openly and honestly. Participants should be reassured about the confidential nature of the interview and that all comments will be anonymised before use.

### Topics and areas of questioning

### A: Awareness of PROMs

- Have you ever completed questionnaires about your QoL or experiences of receiving dialysis before?
- 2. Having looked at the sample questionnaires do they capture the things you think are most important about living with kidney disease and being on dialysis
- 3. Do you think the collection of PROM questionnaires would be beneficial? Do you think the capture of these outcomes is important?

### **B. Practical Aspects around PROM collection**

- 1. Would you be able to complete a PROM questionnaire successfully on your own, and if not, how much assistance do you think you would require?
- 2. How often should they be completed and how long should completion take?

Version 2.0 31.10.17

3. Where and when would you want to complete the PROMs i.e. at home? At the Unit? Before or during dialysis?

4. How should PROM data be collected i.e. in paper or electronic formats such as mobile app or telephone recognition systems?

### C. Feedback of PROM data

1. How would you like to receive feedback from the clinical team on your PROM data? i.e. email, letter, graphs in person etc.

### D. Barriers or facilitators

- 1. What do you think are the likely factors (barriers and facilitators) that may improve or discourage the completion of PROMs?
- 2. What do you think are the issues about PROM collection in different patient groups (e.g. older patients, patients of non-white ethnicity)?

### E. Use of PROMs in Research

- Have you have been involved in PROM collection for research purposes?
- 2. Should PROMs that collect data for routine clinical and research purposes be different?
- 3. Do you think any of the practical considerations change when you are collecting PROMs for research rather than as part of routine practice? i.e. would you be prepared to complete them more often for research
- 4. Are there any special considerations to be given to feedback when using PROMs in a research setting?

### **PROM-HD Study**

Using patient reported outcome measures (PROMs) to promote quality of care and safety in the management of patients with established kidney disease requiring treatment with haemodialysis

### **Topic Guide - HCP Interviews**

### **Research Objectives**

To explore the feasibility of using routine PROM assessment to aid the management of patients with established renal failure undergoing HD

### **Respondent Profile**

Healthcare Professionals (HCPs) who meet the study inclusion/exclusion criteria.

### Logistics

Interview: place, date, and time (start and end) of the interviews to be recorded.

### Introduction

Introduce self as a Nurse Researcher but explain that whilst I have a nursing background I am not part of the direct healthcare team, so please feel to talk openly and honestly. Participants should be reassured about the confidential nature of the interview and that all comments will be anonymised before use.

### Topics and areas of questioning

### A: Awareness of PROMs

1. Have you ever been involved in the collection of PROMs or data regarding QoL and patient experience before?

Do you think the collection of PROM questionnaires would be beneficial?

Do you think the capture of these outcomes is important? What do you think about the current measures available and the use of core outcome sets.

Do you think they could help focus a consultation? Should a 'good' clinician already be able to elicit those outcomes that are important to a patient? Would PROMs alter the way a clinician talks or engages with a patient?

If yes, how, do you think they could help improve care for a group of patients?

Do you think they could assist in the multidisciplinary team (MDT) care/follow up of the patient?

How much time do you spend talking to patients in a typical consultation? Would you like to spend more/less?

2. Having looked at the sample questionnaires – do they capture the things you think are most important about living with kidney disease and being on dialysis from your

Version 5.0 10.10.2019

perspective as a MDT member?

- a. Are there specific aspects of dialysis care that you think would be effected by the use of PROMs
- b. How do you think PROMs differ from PREMs? Do you think collection of one is more important than the other?

### **B. Practical Aspects around PROM collection**

- 1. Do you think most patients would be able to complete a PROM questionnaire successfully on their own, and if not, how much assistance do you think they would require and from whom? Could assistance affect the responses?
- 2. How often should they be completed and how long should review of the results take?
- 3. Where and when would you want the PROMs completed i.e. at home? Before or during dialysis?
- 4. How should PROM data be collected i.e. in paper or electronic formats such as mobile app or telephone recognition systems?

### C. Feedback of PROM data

- 1. Who would be the best member of the MDT to review the data initially? What about alerts? How should they be managed? Some staff said they don't have time, is that true?
- 2. What might be the best way the feedback the PROM data to the (a) clinical team, (b) patient? i.e. email, letter, graphs in person etc.
- 3. How to do you deliver your QA results?
- 4. How do you feel dealing with problems that you can't solve do you feel there are areas outside your area of expertise you would not want to discuss? Is listening enough?
- 5. Specifically, what PROM data do you think would be important within (a) a clinic environment, (b) an MDT meeting, and how might it be presented? E.g. line graphs, bar charts, raw tabulated data etc.
- 6. Could they be used to show longitudinal trends? Do you think they would be able to pick up ceiling effects or sensitive changes?

### D. Barriers or facilitators

- 1. What do you think are the likely factors (barriers and facilitators) that may improve or discourage the completion of PROMs? IT issues/time? Importance of leadership during any implementation phase
- 2. Is there a risk we are going to overburden patients with multiple questionnaires? Have you heard of CAT/item banking?

Version 5.0 10.10.2019

- 3. What is the best way to implement into your workflow could they affect your work flow patterns?
- 4. Would you want educating about PROMs what form would that learning take? What specifically would you want more information on? Theory behind collection of PROS, Core outcome sets? Measures available, how they may be used in routine care?
  - Are there opportunities to undertake advanced communications training?
- 5. What do you think about are the key issues about PROM collection in different patient groups (e.g. older patients, patients of non-white ethnicity)?

### E. Use of PROMs with patients undergoing Home HD

- 1. In your opinion, how do patients dialysing at home differ from those dialysing in satellite units? Are they better at 'coping', dealing with change or is it their support structures? Do you think there is utility measuring PROs with this group of patients in particular? Role of carers in this group, how much should they be involved in the process?
- 2. Would any of your answers differ for patients undergoing Home HD in terms of when, where, how often, who should review and provide feedback?
- 3. Do you think Home HD patients are more likely to engage with digital technology?

### F. Use of PROMs in Research

- 1. Have you have been involved in PROM use for research purposes? do you know how the measurement tool was chosen? Do you think it captured outcomes that were relevant for the research project?
- 2. Do you think it would be a good idea to use core outcome sets for renal trials? Should outcomes and the associated PROM that collects them differ between use for routine clinical and research purposes?
- 3. Do you think any of the practical considerations change when you are collecting PROMs for research rather than as part of routine practice? i.e. how often and where they are completed
- 4. Are there any special considerations to be given to feedback when using PROMs in a research setting?

# Supp Table 1 Patient saturation table and interview characteristics

Patient Interviews Number invited/Number participating Reasons for non-participation

41/22 Did not meet eligibility criteria, did not want to participate (transport issues, did not want to do research)

Range 24-84 Duration of patient interviews (min)

Mean 50 mins

Value

110  $15^{\text{th}}\ interview$ 

**Patient Saturation Data** No of codes generated

Point of data saturation

Note n=17

		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22
1 Innovation Cha	aracteristics																						
1A Innovation S	ource												X						X				
1B Evidence stre	ngth and quality	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/
1C Relative Advantage	Perception of advantage	X	X		X	X	X	X			X	X	X		X	X	X		X		X	X	
C	Intractable problems								X			X		X	X	X					X		
	Potential to cause anxiety										X			X	X		X			X	X	X	
1D Adaptability	Adaptability of intervention Use within research Importance of choices in how and what is answered	X X	X X	X X	X			X X	Х			х	X X X	х		х	x x	x	x x			X	
1E Trialability		/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/
IF Complexity								X											X				
IG Design and	Frequency	X	X		X		X	X		X	X	X		X	X	X	X			X		X	X
Packaging	Length	X	X	X	X		X	X		X	X	X	X	X	X	X	X	X	X	X	X		X
	Language/Readability					X		X	X	X	X	X	X		X		X	X			X		X
	Mode	X	X	X	X	X	X	X	X	X	X	X		X	X	X	X	X	X	X	X	X	X

Supp Table 1 Patient saturation table and interview characteristics

		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22
	Setting	X		Х	X	X		X	X		X	X	X	X		Х	X	X		Х	X	X	X
	Timing	X	X		X	X	X		X	X	X			X	X	X		X	X	X		X	X
	Outcomes that matter	X	X		X	X	X			X			X	X	X	X			X	X		X	
	Current Measures				X	X	X	X	X		X	X	X	X	X		X	X	X		x	X	X
	Safety Alerts	X																	X			X	
	Self-help information		X						X				X	X			X					X	
	ComputerAdaptiveTechnology										X	X		X		X	X		X	X			
	Review and Feedback	X	X		X		X	X	X	X	/	X	X	/	X	X	/	X	X	X		X	X
	Sensitivity to change	/	/	/	/	/	/	/	/	/		/	/		/	/		/	/	/	/	/	/
IH Cost																			Х				
2 Outer Setting																							
2A Needs and	Identification		X	Х	Х		X	Х	Х			Х	Х	X	X			Х	Х	Х	Х	Х	X
resources																							
	Barriers	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	Facilitators	X	X	X	X		X			X	X	X	X	X				X	X	X		X	
2B Cosmopolitai	nism			X				X			X				X					Х			
2C Peer Pressure		/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/
2D External poli	cies and incentives	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/
3 Inner Setting																							
3A Structural Ch	naracteristics															X							
3B Networks and	d Nature and Quality		X	Х	Х	X	Х	Х	X	X	Х	Х	Х		Х	Х		х	Х	Х	х	х	X
Communications																							
	Shared Decision Making	X	X	X							X	X	X	X	X	X		X		X	X		X
3C Culture											Х			X	X	Х					х	1	
3D																						<u> </u>	
Implementation	Tension for change		X	X					X			X	X	X	X			x	X	X	x		x
Climate	Compatibility							X				X	X									X	X
	Relative Priority	X			X						X										X	X	
	Organisational Incentives	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/
	2-5	<u>'</u>	<u>'</u>	<u>'</u>	<u> </u>	<u>'</u>	<u> </u>	<u> </u>	<u>'</u>	<u> </u>	L <u>'</u>	L	<u> </u>	L	L <u>.</u>	L	L	<u>'                                     </u>	L <u></u>	L	<u>'                                     </u>	<u> </u>	لـــــــا

# Supp Table 1 Patient saturation table and interview characteristics

		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22
	Goals and Feedback	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/
	Learning Climate												X										
3E Readiness	Leadership Engagement	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/
for	Available Resources		X		X											X		X				X	
Implementation	Access to knowledge and info		X			X	X						X		X	X	X				X	X	X
4 Characteristic	es of Individuals																						
Knowledge and l		X	X	X	X			X	X	X		X		X	X	X	X	X	X	X	X	X	
Self-efficacy	Ability to self-complete	X	X	X		X	X	X	X	X	X	X	X	X	X	X	X	X		X		X	
	Patient as an Expert			X				X				X	X	X	X					X			
	PROMs v PREMs		X		X	X		X											X		X		
Individual	Previous experience of PROMs	X			X	X	X		X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
stage of change	usage																						
	fication with organisation	X	X		X	X	X	X	X	X	X	X	X	X	X		X			X	X	X	X
Other personal	Multidimensionality of ESKD:																						
attributes	Symptomology	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
	Life on Dialysis	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
5 Process																							
5A Planning		/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/
5B Engaging																							
	Opinion Leaders	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/
	Formally appointed leaders					X		X															
	Champions					X							X	X									
	External Change Agents	/	/	/	/	/		/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/
	Key Stakeholders	/	/	/	/	/		/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/
	Innovation Participants				X								X										
	Role of Carers	X		X	X		X	X		X			X				X						
5C Executing	18 1 :	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/
5D Reflecting an	d Evaluating	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/

# Supp Table 1 Patient saturation table and interview characteristics

First time data coded to node in NVIVO	X
Nothing coded to node in NVIVO	/
Nothing coded to node in NVIVO	/

Suppl Table 2 Healthcare Professional Participants: Saturation table and interview characteristics

	Value
HCP Interviews	
Number invited/Number participating	19/17
Reasons for non-participation	Competing clinical commitments
Duration of patient interviews (min)	Range 29-63
	Mean 48 mins
Patient Saturation Data	
No of codes generated	134
Point of data saturation	16 <sup>th</sup> Interview
Note n=17	

Participants n=17		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17
1 Innovation Characteristics																		
1A Innovation Source						Х										х		
1B Evidence strength and qual	lity	Х				Х				Х		Х		Х	Х	Х	х	Х
1C Relative Advantage		Х	Х	х	Х	Х	Х		Х	Х	Х	Х	Х	Х	Х	Х	х	Х
												X	х		х		х	х
	How PROMs might work to deliver advantage		X		Х	х	Х	х	Х	х								
1D Adaptability		X				Х												Х
	Use within research				X	Х							х		х	х	х	
1E Trialability																	Х	
IF Complexity		Х				Х	Х		Х		Х						Х	
IG Design and Packaging		X	х	Х	х	Х	Х	х	Х	Х	х	Х	х	х	х	Х	х	Х
	Frequency	X	х	х	x	x	x	х	x	х	x	x	х	x	x	x		x
	Length			х	х	х	х		х		х	х	х	х	х		х	
	Mode	х	х		х	х			х	х	х	х	х	х		х	х	

### Suppl Table 2 Healthcare Professional Participants: Saturation table and interview characteristics

Participants n=17		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17
	Setting		Х	х	х	х		х	Х	Х	х			х			х	х
	Timing		х	х	х		х		х	х	х	х	х	х	х		х	
	Self-completion		х	х	х	х	х	х				х	х	х	х	х		х
	Outcomes that matter	X	х	х	х		х		х	х	х		х			х		х
	Safety Alerts			х			х				х			х	х	х	х	
	Sensitivity						X		х		х	х						
	Computer Adaptive Technology					X		х	х	х	х	х	х	х		х	х	
	Review and Feedback	X	х	х	х	х	х	х				х	х	х	х	х	х	х
IH Cost														Х		Х		
2 Outer Setting																		
2A Needs and resources						X	Х	х		х	Х	Х	Х	х		х		
	Barriers		х		х	х	х	х	х	х	х	х	х	х	х	х	х	х
	Facilitators			х	х	х			х		х	х	х				х	
2B Cosmopolitanism				Х	х		х	х					х					
2C Peer Pressure																		
2D External policies and incentives	5			х		х	х	х	х					х	х		х	х
3 Inner Setting																		
3A Structural Characteristics		Х	х	х	х		х	х				х	х	х	х			
3B Networks and Communications	5	X		х	х	х		Х	Х	Х	х	х	х		х	х		х
3C Culture		Х	Х	х		х	х	Х			х	х	х			х	х	х
3D Implementation Climate																		
	Tension for change	X	х	х		х			х	х	х			х				
	Task focused approach to care							X	х			х	х		х	х	х	х
	Compatibility	X				х	х		х		х	х					х	
	Relative Priority	X					х								х			
	Organisational Incentives																	
	Goals and Feedback		X			х				х								
	Learning Climate		X	х								х						х
3E Readiness for Implementation	Leadership Engagement		Х									Х						

### Suppl Table 2 Healthcare Professional Participants: Saturation table and interview characteristics

Participants n=17		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17
	Available Resources	Х	х	Х	х	х	Х	х	Х	Х	х	х	х	х	х	х	х	х
	Access to knowledge and info		X	Х	Х	Х		Х	Х	Х	Х		Х				Х	Х
4 Characteristics of Individuals																		
Knowledge and beliefs		X	Х	Х		Х		Х	Х	Х			х		Х		х	Х
Self-efficacy		X	Х	Х		Х	Х		Х	Х	х		Х		Х	х		
	Ability of patients to self-complete	X	х	х	х	х	х	х	х	х	х	х	х	х	х	х	х	х
Individual stage of change	Previous experience of PROMs usage	Х	х	Х	Х	Х	Х	Х	Х	Х	х		х	Х	Х	х	х	
Individual identification with organisation			Х	Х						Х	х		х					
Other personal attributes		Х	х	Х	Х		Х	Х				Х	х	Х	х	х	х	
5 Process																		
5A Planning						X		Х										
5B Engaging						X	Х		Х									х
	Opinion Leaders	X				х	х				х							х
	Formally appointed leaders	X		х	х	Х		х	х	х	х		х		х			х
	Champions		X	х				х			х		х					х
	External Change Agents												х			х		х
	Key Stakeholders					X												
	Innovation Participants					X												
5C Executing																		
5D Reflecting and Evaluating																х		

First time data coded to this node in NVIVO	X
Nothing coded to this node in NVIVO	